Radiation-Related Heart Disease: Up-to-Date Developments

Wenyoung Tan, Xianming Li and Yong Dai

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/67325

Abstract

Approximately 25–30% of patients with cancer undergo thoracic radiation therapy (RT). RT might inadvertently induce heart injury and result in various forms of radiation-related heart disease (RRHD). The main endpoints of RRHD include cardiac death from RT, clinical heart disease (congestive heart disease, ischemic heart disease, and myocardial infarction), and subclinical heart disease (cardiac perfusion defects). Advanced RT techniques, such as breath control, intensity-modulated RT, and image-guided RT, as well as limited target volume definition might spare or avoid cardiac doses and/or volume, which may translate into decreased incidence of RRHD. The total delivered radiation dose to cardiac implantable electronic devices was strongly recommended not to exceed 2 Gy. The treatment strategies of RRHD were based on the various recommended consensus of related heart diseases in cardiology. However, the standardized definitions of the cardiac structures, dose-volume limits during radiation planning design, the optimal dose-volume parameters, and the dose-volume effects of various cardiac substructures warrant further investigation. The recognition, prediction, prevention, and management of RRHD require close collaboration between oncologists and cardiologists.

Keywords: radiation therapy, heart disease, prevention, treatment

1. Introduction

Cancer is a leading cause of death in both developed and less developed countries worldwide, and its health burden is expected to increase rapidly [1]. In 2012, an estimated 14.1 million new cancer cases and 8.2 million deaths occurred worldwide [1]. Currently, approximately 57% of cancer cases and 65% of cancer deaths occur in less developed countries [1]. Worldwide, the new cases or deaths from lung and breast cancer were at the top of the list [1]. In China, in 2015, an estimated 4,292,000 new cancer cases and 2,814,000 cancer deaths...
occurred [2]. Lung cancer is the most common incident cancer and the leading cause of cancer death in China, and esophageal cancer is also commonly diagnosed. Worldwide, lung, esophageal, and breast cancer account for approximately 27% of new cancer cases which means that more than 20% of patients will receive thoracic radiation therapy (RT). Many studies have proven that local RT improves local control and prolongs overall survival [3–11]. However, thoracic RT might inadvertently result in various forms of cardiac toxicity and manifest as clinical and subclinical cardiac disease, termed radiation-related heart disease (RRHD) [12, 13]. In this chapter, we will present the epidemiological data and discuss the possible pathophysiological mechanisms in brief. We will also address the cardiac avoidance techniques and the dose-volume-effect relationship. Although many cytotoxic and molecularly targeted drugs also result in various cardiac toxicities [14], consideration of these is outside the scope of this chapter.

2. Epidemiological data for radiation-related heart disease

Following the use of mantle field radiation for Hodgkin lymphoma in the 1960s, RRHD was recognized because substantial cardiac damage was observed to occur after the whole heart received doses of radiation higher than 30 Gy [12]. Traditionally, RRHD mainly included radiation-related pericarditis, pericardial and myocardial fibrosis, and coronary artery disease, as well as conduction system abnormalities. However, with improvements in RT techniques and refinements in RT delivery, radiation doses to the heart have decreased in the past three decades. For example, in lung and esophageal cancer, the mean heart dose might be >20 Gy [15], while in postoperative RT for breast cancer, it might be <10 Gy [16, 17]. As a reference point, the survivors of the atomic bombings of Japan received up to 4 Gy [18]. The endpoints of RRHD could be categorized as radiation-induced death from heart disease (mortality), clinical manifestations (clinical disease), and imaging or laboratory abnormalities (subclinical disease) [14] as shown in Figure 1.

Breast cancer is a curable disease. Therefore, minimization of anticancer therapy-induced toxicity is an important concern during treatment decision-making. In a study of breast cancer, mortality due to heart disease was increased by 27% (2p = 0.0001) in women who received surgery plus RT compared to the rate in those who did not receive postoperative RT. The proportional excess of vascular deaths was similar in the first decade and the period thereafter (ratio 1·32 vs. 1·27). However, the absolute rates were about three times higher in the second decade and the latter period for the patients with left-sided breast cancer [5]. Exposure to cardiac radiation in the treatment of breast cancer will increase the subsequent rate of ischemic heart disease for more than 10 years after completion of the therapy. In addition, women with cardiac risk factors experience greater increases in risk after thoracic RT. Darby et al. quantified the dose effect of ischemic heart disease in patients with breast cancer who received adjuvant thoracic RT. They found that the rate of major coronary events increased by 7.4% per Gy without an apparent threshold, and the major coronary events included myocardial infarction, coronary revascularization, and death from ischemic heart disease [13, 19]. Even in the era of modern RT, in comparison with patients with right-sided breast cancer, those with left-sided breast cancer experienced a small increase in the risk of percutaneous coronary
intervention (PCI) following RT, and the 10-year cumulative incidences in patients with left-sided and right-sided disease were 5.5 and 4.5%, respectively [20].

Hodgkin lymphoma usually occurs in young patients and is also one of the most curable cancers. Cytotoxic treatment with anthracyclines and vinca alkaloids and RT are the cornerstone choices for therapy of this cancer, and both are associated with the risk of cardiovascular disease. The cardiovascular risks after chemotherapy and RT have been well established [21, 22]. According to data from old cohort studies, Hodgkin lymphoma was usually treated with radiation doses of 35–45 Gy using extended field treatment such as mantle field radiation. The cumulative risks of heart disease among survivors of adult Hodgkin lymphoma are approximately 5–10% at 15 years, 16% at 20 years, and 34% at 30 years, and coronary artery disease, as the most common form, accounts for approximately 40–50% of adverse cardiac events [23]. A recent systemic analysis showed that among 6039 patients with a median length of follow-up of 9 years, 703 patients were recorded to have 1238 first cardiovascular events, which mostly included ischemic heart disease (19%), congestive heart failure (12%), arrhythmia (16%), and valvular disease (11%). The predictors of cardiovascular disease were the mean heart radiation dose per 1 Gy increase (HR 1015) and the dose of anthracyclines per 50 mg/m² increase in cumulative dose (HR 1077) [24]. In a Dutch study conducted to examine the relative and absolute excess risk of cardiovascular disease incidence, 1713 cardiovascular events were detected in 797 patients after a median follow-up of 20 years. Furthermore, 20% of patients with a cardiovascular disease developed multiple events. Mediastinal RT, anthracycline-containing chemotherapy, and smoking are appeared to be additive factors [25]. In addition, the data
from both individuals exposed to radiation during a medical career [26, 27] and survivors of the atomic bombings in Japan [28] proved that radiation was the source of the risk for RRHD.

Cardiac valvular disease is less common, typically has a late onset (10 years after RT), and is related to higher doses (30 Gy) or young age at treatment. Treatment of a large cardiac volume with high doses can produce acute pericarditis, although this is uncommon. At times, this may lead to chronic or delayed reemergence of pericarditis with effusion.

Furthermore, due to the wide use of advanced imaging techniques, more subclinical manifestations are detected. With repeat nuclear imaging to assess changes in regional and global cardiac function after RT for left-sided breast cancer, a prospective clinical study found that volume-dependent perfusion defects occurred in approximately 40% of patients within the first 2 years after RT for left-sided breast cancer, and these perfusion defects were associated with cardiac wall motion abnormalities [29]. In addition, new perfusion defects usually occurred in the anterior left ventricle within 6 months after radiation [30]. The data from the Surveillance, Epidemiology, and End Results Medicare database showed that patients with left-sided breast cancer who had a history of cardiac disease had an increased risk of PCI after thoracic RT, and there was a lower survival rate in those who received PCI. The 10-year cumulative PCI incidence was 5.5% [95% confidence interval (CI) 4.9–6.2%] and 4.5% (95% CI 4.0–5.0%) for patients with left- and right-sided cancer, respectively [20].

For curable cancer types, such as breast cancer and Hodgkin lymphoma, both the radiation dose to the heart and its substructures and the risks and benefits of different regimens for individual patients should be well balanced during treatment decision-making.

3. Pathophysiological mechanisms of RRHD

The detailed pathogenesis of RRHD has been well reviewed [12, 31]. Overall, the endothelial system of blood vessels, particularly the arteries seem to be the critical target structures. After radiation, early functional alterations might include the pro-inflammatory responses and other changes, followed by slow progression [31, 32]. Although experimental animal models will help to elucidate the possible cellular and molecular mechanisms of RRHD, the results from various animals might be species-specific, and caution should be used in extrapolating to humans. In cancer patients, radiation induces macro- and microvascular injury. The former accelerates age-related atherosclerosis and leads to coronary artery disease after several years or decades due to reduced blood flow to the radiated myocardial territory. On the other hand, the latter reduces capillary density and results in decreased vascular reverse, which usually occurs within several months after RT and has only subclinical manifestations [12].

4. Dose-volume effect of RRHD

The dose-volume effect of RRHD is highly dependent on the definition of its endpoints. According to the length of its latency, RRHD could be divided into acute injury, which often manifests within a few months and is usually transient, and chronic toxicities, which often
manifest as congestive heart failure and ischemic heart disease, among others, and occur with a long latency [33]. RRHD can have subclinical manifestations, such as localized cardiac imaging abnormalities on nuclear magnetic resonance imaging or regional wall motion abnormalities on cardiac ultrasonic examination, but manifestations could also be clinical, such as coronary artery disease or myocardial infarction [33].

The accurate definition of the heart and its substructures is critical to the estimation of the radiation dose-volume effect on RRHD. However, the imprecise definition of the heart in treatment planning computed tomography (CT) imaging poses a great challenge [33]. Feng et al. [34] developed a heart atlas to study cardiac exposure to radiation in the treatment of breast cancer. Using this consistent atlas for cardiac structure delineation, we could quantify the causative effects of RT on cardiac morbidity and mortality and study the dose-volume constraints on the heart and its substructures [34] (Figure 2).
In all of the published studies about the dose-volume response relationships of RRHD, mortality from pericarditis, ischemic heart disease, and decreased myocardial perfusion were three main clinical endpoints [33]. Gagliardi et al. [33] (Figure 3) summarized the dose-volume predictors and normal tissue complication probabilities of pericarditis/pericardial effusion, and the results showed that the mean doses to the pericardium (>30 Gy or >26.1 Gy) or mediastinum (>41 Gy) might be the predictors of radiation-induced pericarditis or pericardial effusion. The incidence of pericarditis was 7% (14/198) with a radiation dose of ≤6 Gy; 12% (5/42) with a dose of 6–15 Gy; 19% (23/123) with a dose of 15–30 Gy; and 50% (7/14) with a dose of >30 Gy. Regarding cardiac mortality from ischemic heart disease or myocardial infarction, radiation dose to the mediastinum >30 Gy; 35% of heart volume receiving a radiation dose >38 Gy; mean dose to the whole heart volume > 2.5 Gy; and radiation to the internal mammary chain would be the predictive parameters [33]. When taking cardiac perfusion defects as the clinical endpoints, volume of the left ventricle receiving doses higher than 23 ($V_{23Gy}$) or 33 Gy ($V_{33Gy}$) could predict myocardial perfusion defects [35].

Figure 3. Dose–response curves of radiation-induced cardiac mortality. These data were estimated based on the breast cancer and Hodgkin lymphoma data sets [33] (with permission).

5. Cardiac dose sparing and avoidance techniques

For curable cancers, such as breast cancer and Hodgkin lymphoma, cardiac dose protection and/or avoidance techniques might be beneficial in minimizing RRHD. For breast cancer, several techniques have been utilized clinically. These techniques include the following: (1) RT delivery with breath control or holding techniques, (2) prone patient positioning, (3) new RT techniques such as intensity-modulated RT (IMRT), proton therapy, or partial breast irradiation techniques, and (4) single-fraction, intraoperative radiation [36] (Figure 4).
With breath holding within inspiration, the distance from the chest wall to the heart will increase and the cardiac volume in the field will decrease, the mean or maximal dose to the heart or left anterior descending artery will be reduced [36], and the probability of cardiac mortality will also be reduced (4.8 vs. 0.1%) [37]. In the delivery of RT, patients are immobilized in the prone position so that the breast falls away from the chest wall and the distance from the heart to the RT beam increases. A few studies showed that with this technique, 75–85% of left-sided breast cancer patients had reduced cardiac volume in the field [38] and the mean cardiac dose decreased [39]. Although the main concerns of the prone position include its reproducibility and the potential increase in radiation to other normal tissues due to the poor setup, recent data showed that this technique could be well reproducible with daily cone-beam CT [40, 41].

For breast cancer patients, IMRT has been proven to have a cardiac dose sparing effect without compromising the dose homogeneity in the breast, especially for those with left-sided lesions [36, 42]. With the IMRT technique, the cardiac dose decreased with improved dose homogeneity in the breast [43]. A series of studies showed that, compared with breath holding in three-dimensional conformal RT and prone position techniques, IMRT has similar benefits and is more reproducible. The advantages of IMRT technique included the improvement of radiation dose homogeneity in target volume, the reduction of high cardiac dose volumes, and the decrease of normal tissue complication probability. In addition, IMRT technique showed its advantages in sparing the high-risk cardiac sub-regions such as the anterior part of the heart, the coronary arteries, and the left ventricle [16, 17, 44].

Partial breast irradiation, as an alternative method to reduce the cardiac dose, could decrease the irradiated breast volume and increase the distance from the target volume to the heart. Hypofractionation is required by partial breast irradiation, and two recent reviews suggest that hypofractionation has not resulted in increased cardiac morbidity [45, 46]. Dosimetric studies showed that interstitial brachytherapy could reduce cardiac doses with image-guided RT techniques [47, 48]. The mean cardiac dose decreased to 21% of the prescription dose in patients with left-sided breast cancer [48] and the cardiac volume receiving low doses (5 and 10 Gy) decreased significantly. In addition, the advantages of proton therapy including the rapid dose falloff and the Bragg peak make it possible to spare the radiation dose to the surrounding tissues including the heart. Several dosimetric studies showed that

---

**Figure 4.** Cardiac sparing techniques is available nowadays. These techniques included radiation techniques improvement and patient or organ motion management.
proton RT could reduce the maximal dose, $V_{20Gy}$, $V_{5Gy}$, etc [49–52]. However, because of the limited availability and high cost, at present, this technique is not advocated for cardiac dose sparing [36].

For Hodgkin lymphoma, the RT field has changed over the past decades. Previously, the majority of patients received mantle field radiation with/without upper abdomen field radiation, and a large volume of the heart had a prescribed dose irradiation. According to the anatomical sites of disease presence, the caudal border of the mantle field individually varied from the bottom border at the 8th–9th thoracic vertebrae (T8–T9) [53] to T10–T11 [54, 55], and the higher caudal border might spare most of the irradiated heart volume [53]. With advanced imaging modalities such as positron emission tomography–CT and improved RT delivery techniques such as IMRT, image-guided RT, and breath control techniques, among others, the previously applied extended field and involved field techniques have now been replaced by techniques using limited target volumes, such as involved node RT (INRT) and involved site RT (ISRT) [56]. With the optimal imaging during the course of treatment, both the INRT and ISRT techniques reduce the treated volume to a safe minimum [56]. In addition, with refinements of Hodgkin lymphoma, the prescription dose decreased to 20–36 Gy [57]. Due to more limited target volume and lower prescribed radiation doses, greater amounts of normal healthy tissues such as lung and heart could be spared.

Theoretically, for RT of non-small cell lung cancer, dose escalation to 74 Gy would be better than the standardized 60 Gy dose. However, the results of a randomized phase 3 study (RTOG 0617) showed that a higher dose did not translate to a better outcome and might even be potentially harmful [58]. One reasonable explanation is that patients receiving doses of 74 Gy usually had worse dose-volume effects on the heart. The dose volume parameters including $V_{5Gy}$ and $V_{30Gy}$ of the heart were the important predictors of patient survival [58]. The dose-volume effects on the heart substructures such as the pericardium, atria, and ventricles will be investigated and their dose-volume limitations will be included in future lung cancer trials. In addition, for early and locally advanced non-small cell lung cancer, proton RT will potentially be used for cardiac sparing [59].

6. Radiation for patients with cardiac implantable electronic devices

The numbers of patients with both cardiac implantable electronic devices (CIEDs) including pacemakers (PMs) and implantable cardiac defibrillators and cancer are expected to rise, and patients in these situations require RT. The potential interactions between high doses of radiation and the function, longevity, and integrity of the CIEDs, as well as the harm to the patients, remain unclear. The results of a recent review [60, 61] showed that the risk of device failure increases with increasing radiation doses, without a clear cutoff point. For patients with pacemakers, the delivered total radiation dose to the device was strongly recommended not to exceed 2 Gy and the dose in patients with implantable cardiac defibrillators should be
within 1 Gy. The radiation energy should be less than 6 MV. Because of the potential dangers of device malfunction, the radiation oncologist should have all the measures designed to minimize the risk to patients. Furthermore, it is necessary for the cardiologist, oncologist, radiotherapist, and physicist to collaborate closely.

7. Treatment strategies of RRHD

Generally, the treatment strategies of various RRHDs are similar to those in normal population [62–64]. For example, radiation-induced left ventricular dysfunction or heart failure could be treated according to the recommended guidelines of heart failure [65]. And for those with anticancer drug-induced hypertension, antihypertensive agents should be individualized to the clinical circumstances of the patients [66]. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers are usually considered for patients with proteinuria, metabolic syndrome, or high risk of chronic kidney disease [66]. Treatment with nondihydropyridine calcium channel blockers should be avoided in patients receiving cytochrome P450 inhibitors, while dihydropyridine calcium channel blockers are preferred in elderly patients [67, 68]. Low-molecular weight heparin for a minimum of 3–6 months is the recommended treatment for patients with newly diagnosed venous thromboembolism [69].

8. Unanswered questions regarding RRHD

Variability in certain risk factors may influence the development of a radiation-associated heart disease. These factors included patients themselves, RT techniques, the evaluable endpoints, and social-psychological variables [19]. The patient-related factors include age, personal alcohol and tobacco history, systemic anticancer drugs with potential cardiac toxicities such as anthracyclines, trastuzumab, taxanes, tamoxifen, and letrozole, among others, individual sensitivity to late heart morbidity, and hereditary heart disease [19]. The definitions of the heart and its substructures are shown in Table 1, and the standardized delineation consensus and atlas should be consulted by radiation oncologists. For the heart and cardiac substructures, further investigation should be conducted regarding which dose-volume limitations were used during the design of radiation planning and what optimal dosimetric parameters were reported to be necessary, such as maximal or mean heart dose, \( V_{5Gy} \), \( V_{10Gy} \), \( V_{20Gy} \) etc. The clinical endpoints included cardiac mortality and radiation-associated clinical and subclinical heart diseases [33]. The optimal RT delivery techniques and reliable methods to evaluate these endpoints will require further studies. The designation of RRHD might unavoidably increase the psychological burden of patients. In addition, to find those patients who may develop late RRHD, health economic evaluations should be critically performed prior to the initiation of screening programs [19].
| Substructure                              | Definition                                                                 | Note                                                                                                                                 |
|-----------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Heart [16, 34, 70]                      | Cranial: The whole heart starts just inferior to the left pulmonary artery | If contrast is administered, the superior vena cava (SVC) can generally be separately contoured from the whole heart. In a noncontrast scan, the SVC can be included for simplification and consistency |
|                                          | Caudal: The heart blends with the diaphragm                                |                                                                                                                                       |
| Pericardium [34]                        | The whole heart                                                           | Cardiac vessels run in the fatty tissue within the pericardium and should be included in the contours                               |
| Left atrium [34]                        | Begins just inferior to the left pulmonary artery                          | –                                                                                                                                 |
| Left ventricle [16, 34]                 | The visible heart according to both CT images and heart anatomy            | Typically, anterior and to the left of the left atrium                                                                          |
| Right atrium [34]                       | No                                                                        | Starts to the right of the aortic root superiorly                                                                              |
| Right ventricle [34]                    | No                                                                        | Lies directly beneath the sternum and connects to the pulmonary trunk                                                           |
| Left main coronary artery [34, 70]      | Defined from its origin in the aortic sinus to the first branches         | Originates from the left side of the ascending aorta, inferior to the right pulmonary artery                                     |
| Right coronary artery [34, 70]          |                                                                           | Originates from the right side of the ascending aorta                                                                          |
| Left anterior descending artery [34, 70] | Defined from where they branched at the left or right main coronary artery | Originates from the left coronary artery and runs in the interventricular groove between the right and left ventricles            |
| Left circumflex artery [34, 70]         |                                                                           | Originates from the left coronary artery and runs between the left atrium and ventricle                                          |
| Right marginal artery [34, 70]          |                                                                           | –                                                                                                                                 |
| Aortic valve [34]                       | No                                                                        | Found within the ascending aorta and seen in cross section on axial CT                                                          |
| Pulmonic valve [34]                     | No                                                                        | Found within the pulmonary trunk and seen in cross section on axial CT                                                          |
| Tricuspid valve [34]                    | No                                                                        | Located between the right atrium and ventricle. It is difficult to see, but it is defined as the area where the blood pool between the atrium and ventricle is shared |
| Mitral valve [34]                       | No                                                                        | Located between the left atrium and ventricle. It is difficult to see, but it is defined as the area where the blood pool between the atrium and ventricle is shared |
| Atrioventricular node [34]              | No                                                                        | Cannot be seen on CT. It is located on the basal portion of the interventricular septum and extends between the right atrium and ventricle |
| Anterior myocardial territory [16, 17, 70]| Comprises the myocardium from the anterior surface of the heart up to    | It is an imaged subregion in the anterior port of the heart as a high-risk region for breast cancer radiation therapy               |
|                                          | 1.0 cm posterioly and the main branches of the coronary arteries at the   |                                                                                                                                     |
|                                          | anterior portion of the heart                                             |                                                                                                                                     |

Table 1. Recommended delineations of the heart and substructures.
9. Conclusion

As a significant radiation-induced toxicity, RRHD should not be neglected during clinical decision-making, especially for patients who could be cured by modern anticancer modalities. RRHD includes radiation-induced death from heart diseases, as well as clinical and subclinical heart disease. Advanced RT techniques including breath control, IMRT, and imaging-guided RT might be used to avoid or spare cardiac doses and/or volume, which might translate into decreased incidence of RRHD. Furthermore, the significance and implications of RRHD differ depending on the clinical scenario; therefore, a consensus has not yet been reached regarding the recommended dose-volume limits. It is prudent to minimize the cardiac dose/volume and optimize the patient cardiovascular risk profiles. The recognition, prevention and prediction, and treatment of RRHD should be within the domain of oncocardiology, which requires close collaboration between oncologists and cardiologists [14, 63].

Acknowledgements

This work was granted by Shenzhen Scientific Innovation in basic research project JCYJ20160422162900408 and Shenzhen Sanming Project.

Author details

Wenyong Tan*, Xianming Li and Yong Dai

*Address all correspondence to: tanwyyym@hotmail.com

Department of Oncology, The Second Clinical Medical College (Shenzhen People’s Hospital), Ji’nan University, Shenzhen, China

References

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. Mar 2015;65(2):87–108.

[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians. Mar 2016;66(2):115–132.

[3] Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. Nov 12 2011;378(9804):1707–1716.
[4] Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. _Lancet_. May 14–20 2005;365(9472):1687–1717.

[5] Group EBCTC. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. _Lancet_. May 20 2000;355(9217):1757–1770.

[6] Group EBCTC. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. _The Lancet_. 2014;383(9935):2127–2135.

[7] Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. _Lancet_. Aug 1 2009;374(9687):379–386.

[8] Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. _Journal of Clinical Oncology_. May 1 2010;28(13):2181–2190.

[9] Rodrigues G, Choy H, Bradley J, et al. Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. _Practical Radiation Oncology_. May-Jun 2015;5(3):141–148.

[10] Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. _The Lancet Oncology_. Sep 2015;16(9):1090–1098.

[11] Rustgi AK, El-Serag HB. Esophageal carcinoma. _The New England Journal of Medicine_. Dec 25 2014;371(26):2499–2509.

[12] Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. _International Journal of Radiation Oncology Biology Physics_. Mar 1 2010;76(3):656–665.

[13] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. _The New England Journal of Medicine_. Mar 14 2013;368(11):987–998.

[14] Tan W, Wu X, Wei S. Chemoradiotherapy-associated cardiovascular toxicity: a need of cardio-oncology to improve. _Journal of Clinical & Experimental Cardiology_. J Clin Exp Cardiolog 5:320.

[15] Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. _Journal of Clinical Oncology_. Jun 20 2015;33(18):2100–2105.
[16] Tan W, Wang X, Qiu D, et al. Dosimetric comparison of intensity-modulated radiotherapy plans, with or without anterior myocardial territory and left ventricle as organs at risk, in early-stage left-sided breast cancer patients. *International Journal of Radiation Oncology Biology Physics*. Dec 1 2011;81(5):1544–1551.

[17] Tan W, Liu D, Xue C, et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. *International Journal of Radiation Oncology Biology Physics*. Apr 1 2012;82(5):1689–1697.

[18] Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950–1997. *Radiation research*. Oct 2003;160(4):381–407.

[19] Offersen B, Hojris I, Overgaard M. Radiation-induced heart morbidity after adjuvant radiotherapy of early breast cancer—Is it still an issue? *Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology*. Aug 2011;100(2):157–159.

[20] Boero IJ, Paravati AJ, Triplett DP, et al. Modern radiation therapy and cardiac outcomes in breast cancer. *International Journal of Radiation Oncology Biology Physics*. 2016;94(4):700–708.

[21] Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood*. Mar 1 2007;109(5):1878–1886.

[22] Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. *Journal of the National Cancer Institute*. Feb 7 2007;99(3):206–214.

[23] Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology American Society of Hematology Education Program 2011;2011:323–9.

[24] Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. *Lancet Haematology*. Nov 2015;2(11):e492–502.

[25] van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. *JAMA Internal Medicine*. Jun 2015;175(6):1007–1017.

[26] Yan X, Sasi SP, Gee H, et al. Cardiovascular risks associated with low dose ionizing particle radiation. *PloS One*. 2014;9(10):e110269.

[27] Hauptmann M, Mohan AK, Doody MM, Linet MS, Mabuchi K. Mortality from diseases of the circulatory system in radiologic technologists in the United States. *American Journal of Epidemiology*. Feb 1 2003;157(3):239–248.

[28] Okubo T. Long-term epidemiological studies of atomic bomb survivors in Hiroshima and Nagasaki: study populations, dosimetry and summary of health effects. *Radiation Protection Dosimetry*. Oct 2012;151(4):671–673.
[29] Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. International Journal of Radiation Oncology Biology Physics. Sep 1 2005;63(1):214–223.

[30] Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer. Oct 15 2007;110(8):1840–1850.

[31] Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? International Journal of Radiation Oncology Biology Physics. Jan 1 2007;67(1):10–18.

[32] Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. The American Journal of cardiology. Nov 15 2013;112(10):1688–1696.

[33] Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. International Journal of Radiation Oncology Biology Physics. Mar 1 2010;76(3 Suppl):S77–85.

[34] Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. International Journal of Radiation Oncology Biology Physics. Jan 1 2011;79(1):10–18.

[35] Das SK, Baydush AH, Zhou S, et al. Predicting radiotherapy-induced cardiac perfusion defects. Medical Physics. Jan 2005;32(1):19–27.

[36] Shah C, Badiyan S, Berry S, et al. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2014;112:9–16.

[37] Korreman SS, Pedersen AN, Aarup LR, Nottrup TJ, Specht L, Nystrom H. Reduction of cardiac and pulmonary complication probabilities after breathing adapted radiotherapy for breast cancer. International Journal of Radiation Oncology Biology Physics. Aug 1 2006;65(5):1375–1380.

[38] Lymberis SC, deWyngaert JK, Parhar P, et al. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. International Journal of Radiation Oncology Biology Physics. Nov 15 2012;84(4):902–909.

[39] Fernandez-Lizarbe E, Montero A, Polo A, et al. Pilot study of feasibility and dosimetric comparison of prone versus supine breast radiotherapy. Clinical & Translational Oncology. Jun 2013;15(6):450–459.

[40] Jozsef G, DeWyngaert JK, Becker SJ, Lymberis S, Formenti SC. Prospective study of cone-beam computed tomography image-guided radiotherapy for prone accelerated partial breast irradiation. International Journal of Radiation Oncology Biology Physics. Oct 1 2011;81(2):568–574.
[41] De Puysseleyr A, Mulliez T, Gulyban A, et al. Improved cone-beam computed tomography in supine and prone breast radiotherapy. Surface reconstruction, radiation exposure, and clinical workflow. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft … [et al]. Nov 2013;189(11):945–950.

[42] Arthur DW, Morris MM, Vicini FA. Breast cancer: new radiation treatment options. Oncology (Williston Park). Nov 2004;18(13):1621–1629; discussion 1629–1630, 1636–1638.

[43] Li JG, Williams SS, Goffinet DR, Boyer AL, Xing L. Breast-conserving radiation therapy using combined electron and intensity-modulated radiotherapy technique. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. Jul 2000;56(1):65–71.

[44] Lohr F, El-Haddad M, Dobler B, et al. Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. International Journal of Radiation Oncology Biology Physics. May 1 2009;74(1):73–80.

[45] Badiyan SN, Shah C, Arthur D, et al. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. Jan 2014;110(1):39–44.

[46] Shaitelman SF, Khan AJ, Woodward WA, et al. Shortened radiation therapy schedules for early-stage breast cancer: a review of hypofractionated whole-breast irradiation and accelerated partial breast irradiation. The Breast Journal. Mar-Apr 2014;20(2):131–146.

[47] Major T, Polgar C, Lovey K, Frohlich G. Dosimetric characteristics of accelerated partial breast irradiation with CT image–based multicatheter interstitial brachytherapy: a single institution’s experience. Brachytherapy. Sep-Oct 2011;10(5):421–426.

[48] Major T, Frohlich G, Lovey K, Fodor J, Polgar C. Dosimetric experience with accelerated partial breast irradiation using image-guided interstitial brachytherapy. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. Jan 2009;90(1):48–55.

[49] Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. International Journal of Radiation Oncology Biology Physics. Mar 1 2003;55(3):785–792.

[50] Johansson J, Isacsson U, Lindman H, Montelius A, Glimelius B. Node-positive left-sided breast cancer patients after breast-conserving surgery: potential outcomes of radiotherapy modalities and techniques. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. Nov 2002;65(2):89–98.

[51] Ares C, Khan S, Macartain AM, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? International Journal of Radiation Oncology Biology Physics. Mar 1 2010;76(3):685–697.
[52] Jimenez RB, Goma C, Nyamwanda J, et al. Intensity modulated proton therapy for post-mastectomy radiation of bilateral implant reconstructed breasts: a treatment planning study. *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology*. May 2013;107(2):213–217.

[53] Ng AK, Li S, Neuberg D, et al. Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin’s disease. *Annals of Oncology*. Nov 2006;17(11):1693–1697.

[54] Page V, Gardner A, Karzmark CJ. Physical and dosimetric aspects of the radiotherapy of malignant lymphomas. I. The mantle technique. *Radiology*. Sep 1970;96(3):609–618.

[55] Anderson H, Deakin DP, Wagstaff J, et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin’s disease PS IA-IIIB: a report from the Manchester lymphoma group. *British Journal of Cancer*. Jun 1984;49(6):695–702.

[56] Specht L, Yahalom J, Illidge T, et al. Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). *International Journal of Radiation Oncology Biology Physics*. Jun 18 2013.

[57] Ansell SM. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic proceedings 2015;90:1574–83.

[58] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *The Lancet Oncology*. 2015;16(2):187–199.

[59] Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. *International Journal of Radiation Oncology Biology Physics*. May 1 2016;95(1):505–516.

[60] Tajstra M, Gadula-Gacek E, Buchta P, Blamek S, Gasior M, Kosiuk J. Effect of therapeutic ionizing radiation on implantable electronic devices: systematic review and practical guidance. *Journal of Cardiovascular Electrophysiology*. 2016;27:1247–51.

[61] Salerno F, Gomellini S, Caruso C, et al. Management of radiation therapy patients with cardiac defibrillator or pacemaker. *La Radiologia Medica*. Jun 2016;121(6):515–520.

[62] Shu J, Zhou J, Patel C, Yan GX. Pharmacotherapy of cardiac arrhythmias—basic science for clinicians. *Pacing and Clinical Electrophysiology: PACE*. Nov 2009;32(11):1454–1465.

[63] Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA: A Cancer Journal for Clinicians*. Jul 2016;66(4):309–325.

[64] Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Annals of Oncology*. Oct 2012;23 Suppl 7:vii155–166.
[65] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. Oct 15 2013;62(16):e147–239.

[66] James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA: The Journal of the American Medical Association*. 2014;311:507–20.

[67] Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. *Annals of Oncology*. May 2009;20(5):807–815.

[68] Lackland DT. Hypertension: Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure guidelines. *Current Opinion in Neurology*. Feb 2013;26(1):8–12.

[69] Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. *The Lancet Oncology*. 2016;17(10):e452–e466.

[70] Tan W, Xu L, Wang X, Qiu D, Han G, Hu D. Estimation of the displacement of cardiac substructures and the motion of the coronary arteries using electrocardiographic gating. *OncoTargets and Therapy*. 2013;6:1325–1332.
